Advances in cryptorchidism, VUR deliver key benefits

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.